Business
GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel
PARIS, December 22, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that Israel’s Ministry of Health Pharmaceutical Division has authorized the use of the candidate gene therapy GS010/LUMEVOQ®1 for the early access treatment of individual patients in the country.
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/4354c562762be32823e7aa8c8ea820a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/O1SpaTes_PO7EAmPshRrRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4354c562762be32823e7aa8c8ea820a6","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Israel’s Ministry of Health authorizes individual patients early access treatment with GS010/LUMEVOQ®, a candidate gene therapy for the treatment of ND4-LHON.","length":158,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Bilateral injection expected to be performed in Q1 2026.","length":56,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":214,"olType":false},{"type":"text","content":"PARIS, December 22, 2025--(BUSINESS WIRE)--Regulatory News:","length":59,"tagName":"p"},{"type":"text","content":"GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that Israel’s Ministry of Health Pharmaceutical Division has authorized the use of the candidate gene therapy GS010/LUMEVOQ®1 for the early access treatment of individual patients in the country.","length":452,"tagName":"p"},{"type":"text","content":"Early access treatment in Israel is potentially available to patients with a life‑threatening or seriously debilitating disease who cannot be properly treated with a registered and approved medicinal product in Israel or abroad and who cannot be included in an appropriate clinical trial. As in many countries, the decision to treat must be initiated by a patient’s physician, after which the treating hospital’s ethics committee (Helsinki Committee) and Ministry of Health must both approve treatment. The application for early access treatment includes the scientific rationale for the treatment and evidence from non-clinical and clinical studies as well as professional literature that support the benefit-risk assessment for the patient. The Company is working with SK-Pharma, ...